The cortisone shots market is witnessing a surge in demand due to the increasing prevalence of musculoskeletal disorders. Conditions such as arthritis, tendinitis, and bursitis are on the rise, driving the need for cortisone injections as a common and effective treatment option to alleviate inflammation and pain.
A growing old age population is one of the principal market dynamics. With advancing years, people are highly likely to develop joint-related problems and inflammatory disorders. Cortisone shots become the preferred choice of health practitioners for pain management and improving the quality of life of elderly patients.
Cortisone shots are widely used in orthopedics, what affects the market trends. These injections are advised by orthopedic specialists to control joint pain and inflammation due to the disorders such as osteoarthritis. The increasing range of orthopedic applications further promotes the overall market growth.
The sports medicine industry is one of the determinants of cortisone shots market dynamics. Cortisone injections are commonly used by athletes to hasten the recovery from sports injuries like tendonitis or ligament strains. The sports community support of these injections influences their popularization and market appeal.
Pain management clinics are key players in shaping the market. Many such specialized clinics also deliver cortisone shots in the context of a holistic pain management treatments. The rise of such clinics worldwide also adds to easier access and use of cortisone injections.
Continued developments in injection techniques and related technologies improves the accuracy and effectiveness of cortisone injections. Changes in needle design, imaging guidance, and injection methods allow targeted delivery of corticosteroids which affects market dynamics through the optimization of treatment outcomes.
The increased choice of patients for non-surgical interventions affects cortisone shots market dynamics. The ease of cortisone shots as compared to surgical methods has led patients to go for injections to control pain and inflammation, with an impact on the market growth in general.
Regulation environment is the very foundation of the market dynamics. Regulations are strict with regard to production, distribution, and administration of cortisone shots which make the market hard to enter and the competitors to compete. Regulatory standards compliance is important for stakeholders for the safety and efficacy of the product.
Biotechnological innovations strengthen the dynamic cortisone shot’s landscape. Advanced formulations, which provide extended-release corticosteroids, provide long-term therapeutic effects, thus, reducing the frequency of injections. Market pays attention to those innovations, which affects treatment preferences.
Changes in healthcare reimbursement policies influence the affordability and accessibility of cortisone shots. Variations in reimbursement rates and policies impact patient choices and healthcare provider decisions, shaping the market dynamics by influencing the financial aspects of cortisone shot administration.
The Cortisone Shots Market Size was valued at USD 2.74 Billion in 2023. The Global Cortisone Shots industry is projected to grow from USD 2.95 Billion in 2024 to USD 4.93 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.85% during the forecast period (2024 - 2032).
Also known as cortisone injections, cortisone shots are used to relieve pain and inflammation in case of injury to the joints or other parts of the body. They are most commonly used to treat inflammation at the joints such as knee, spine, ankle, elbow, hip, shoulder and wrist, and are usually administered in a clinical setting with the doctor’s approval. Cortisone injections have a similar anti-inflammatory action to other corticosteroids. It is composed of corticosteroid medication and a local anesthetic. Due to the potential side effects of cortisone shots, the number of doses administered to a patient is limited. Major indications for the use of cortisone shots are arthritis, skin diseases, tendinitis, and other sport injuries.
In November 2022, Anika Therapeutics, Inc., a worldwide firm specializing in preserving joints, has reported that Cingal® successfully achieved its main objective in a Phase III Study (Cingal 19-01). The study showed that Cingal® was superior to triamcinolone hexacetonide (TH) steroid alone in the 26 weeks following therapy. The Cingal 19-01 Phase III study is the third fully completed Phase III research of Cingal. It has shown superiority above both its active ingredients and placebo, as indicated by prior studies. Throughout the three Phase III studies that have been completed, Cingal exhibited an average pain improvement of 71% compared to the initial condition. Additionally, an average of 91% of the participants who received Cingal were considered to be Responders. Cingal is a composite product consisting of cross-linked hyaluronic acid (HA) that has been scientifically demonstrated to offer enduring pain relief for a period of at least 6 months. Additionally, it contains a TH steroid that provides rapid but temporary pain relief. Both components of Cingal have received approval for commercial distribution in the United States, specifically for the treatment of knee osteoarthritis (OA) pain. Cingal is presently distributed in over 35 countries worldwide, excluding the United States. Anika plans to collaborate with the U.S. Food and Drug Administration (FDA) in the upcoming months to discuss the necessary actions for obtaining regulatory approval in the United States. Simultaneously, Anika is investigating the possibility of promoting Cingal through business collaborations in the United States and specific Asian markets. These endeavors will provide information for determining the further actions, including whether and in what manner to proceed with another clinical trial in the United States.
Rising prevalence of chronic diseases such as rheumatoid arthritis, tendinitis, and bursitis, increasing number of injuries to the joints, muscles and tendon, and the presence of key players in the market are important driver that accelerate the growth of the market. Rising geriatric population is another key driver for the market growth due to increasing prevalence of arthritis among the elderly. However, cortisone shots exhibit a number of disadvantages such as damage to the tendons, ligaments, and articular cartilage, thus restricting the growth of the market.
World Health Organization, Centers for Disease Control and Prevention (CDC), European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation
Research Methodology
Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation
Segments
The global cortisone shots market is segmented on the basis of type, indication, and end user.
On the basis of type, market is segmented into articular or joint injections, epidural steroid injection, trigger point injection, and others.
On the basis of indication, the market is segmented into rheumatoid arthritis, psoriatic arthritis, bursitis, allergic reaction, skin conditions, and others.
On the basis of end user, the market is segmented into hospitals, clinics, sport medicine centers, pharmaceutical companies, and others.
Regional Analysis of the Global Cortisone Shots Market
America acquires the first position in the market for cortisone shots owing to the rising prevalence of various types of allergies, arthritis, tendinitis, and others, and rising demand for corticosteroid injection in the U.S. According to the Center for Disease Control and Prevention, an estimated 78 million i.e. 26% of the U.S. adults aged 18 years or older are projected to have doctor-diagnosed arthritis by 2040. Additionally, the prevalence of tendinitis among athletes is found to be increasing from last few years in the U.S.
Europe is the second largest market for cortisone shots owing to the rising prevalence of rheumatoid arthritis in European countries, and availability of funds for research and development activities. Also, rising prevalence of allergic conditions such as asthma, food allergy, and anaphylaxis, increasing demand for diagnostic services and rising awareness about the use of cortisone injections for the treatment of tendinitis fuels the market growth.
The market in Asia Pacific is expected to grow at the fastest pace and is driven by the rising prevalence of diabetes, obesity, which act as risk factors for rheumatoid and osteoarthritis which is further posed to propel the growth of the market. Furthermore, rising awareness about sport injuries and the use of cortisone shots for their treatment, influences the growth of the market positively.
The Middle East & Africa also show a steady rise in the market owing to high prevalence of chronic diseases such as obesity and diabetes, and improving healthcare infrastructure. Increasing demand for new treatment options for sport injuries also influences the market growth in the Middle East & African countries.
Key Players in the Global Cortisone Shots Market
Some of the key players in this market are Merck & Co., Inc. (U.S.), Pfizer (U.S.), Bristol-Myers Squibb Company (U.S.), Novartis AG (Germany), GlaxoSmithKline (U.S.), Pharmascience Inc. (U.S.), Farmabios SPA (Italy), AdvaCare Pharma (U.S.), and others.
Intended Audience
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)